Literature DB >> 27040384

Tanshinone ⅡA inhibits human esophageal cancer cell growth through miR-122-mediated PKM2 down-regulation.

Hong-Sheng Zhang1, Feng-Juan Zhang2, Hu Li2, Yang Liu2, Guang-Yuan Du2, Ying-Hui Huang2.   

Abstract

Pyruvate kinase M2 (PKM2) plays a pivotal role in the growth, survival and metabolic reprogramming of cancer cells. Here, we presented for the first time that tanshinone ⅡA inhibited human esophagus cancer cell growth through miR-122-mediated PKM2 down-regulation pathway. Tanshinone ⅡA inhibited cell proliferation and induced cell cycle arrest in S phase in human Ec109 cells. As expected, tanshinone ⅡA down-regulated PKM2 mRNA and protein expression in Ec109 cells. Given these findings, we further investigated microRNAs regulation of PKM2 and confirmed miR-122 for targeting PKM2. Moreover, we found that tanshinone ⅡA-induced up-regulation of miR-122 expression inhibited PKM2 expression in Ec109 cells. Meanwhile, tanshinone ⅡA inhibited proliferation through miR122-medated PKM2 down-regulation. It was demonstrated that the anticancer activity of tanshinone ⅡA was targeted at metabolic regulation of miR-122/PKM2 in human esophagus cancer cells. Taken together, our results revealed tanshinone ⅡA targeting at PKM2-mediated metabolic reprogramming play an important role in inhibition of esophageal cancer cell growth.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Metabolic reprogramming; PKM2; Tanshinone ⅡA; miR-122

Mesh:

Substances:

Year:  2016        PMID: 27040384     DOI: 10.1016/j.abb.2016.03.031

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  27 in total

Review 1.  Dysregulation of metabolic enzymes in tumor and stromal cells: Role in oncogenesis and therapeutic opportunities.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Cancer Lett       Date:  2020-01-07       Impact factor: 8.679

2.  KIF22 promotes progress of esophageal squamous cell carcinoma cells and is negatively regulated by miR-122.

Authors:  Jian Wang; Peng-Yi Yu; Jing-Ping Yu; Ju-Dong Luo; Zhi-Qiang Sun; Fei Sun; Ze Kong; Jian-Lin Wang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  MiR-122 targets VEGFC in bladder cancer to inhibit tumor growth and angiogenesis.

Authors:  Yi Wang; Qing-Fei Xing; Xiao-Qiang Liu; Zhan-Jun Guo; Chang-Ying Li; Guang Sun
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

4.  Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.

Authors:  Darshan S Chandrashekar; Balabhadrapatruni V S K Chakravarthi; Alyncia D Robinson; Joshua C Anderson; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Marie-Lisa Eich; Akhilesh Kumar Bajpai; Sravanthi Davuluri; Maya S Guru; Arjun S Guru; Gurudatta Naik; Deborah L Della Manna; Kshitish K Acharya; Shannon Carskadon; Upender Manne; David K Crossman; James E Ferguson; William E Grizzle; Nallasivam Palanisamy; Christopher D Willey; Michael R Crowley; George J Netto; Eddy S Yang; Sooryanarayana Varambally; Guru Sonpavde
Journal:  Oncogene       Date:  2020-03-30       Impact factor: 9.867

5.  LRSSLMDA: Laplacian Regularized Sparse Subspace Learning for MiRNA-Disease Association prediction.

Authors:  Xing Chen; Li Huang
Journal:  PLoS Comput Biol       Date:  2017-12-18       Impact factor: 4.475

6.  Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.

Authors:  Xiaojing Li; Zhifeng Li; Xianping Li; Baoguo Liu; Zhijun Liu
Journal:  BMC Cancer       Date:  2017-05-22       Impact factor: 4.430

7.  Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1.

Authors:  Jiao Yu; Xiaoxia Wang; Yuhua Li; Bin Tang
Journal:  Oncol Rep       Date:  2017-01-30       Impact factor: 3.906

8.  Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN.

Authors:  Qidi Zheng; Zhuojia Lin; Jie Xu; Yanan Lu; Qiuyu Meng; Chen Wang; Yuxin Yang; Xiaoru Xin; Xiaonan Li; Hu Pu; Xin Gui; Tianming Li; Wujun Xiong; Dongdong Lu
Journal:  Cell Death Dis       Date:  2018-02-15       Impact factor: 8.469

Review 9.  Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.

Authors:  Bhagyashri Rathod; Shivam Chak; Sagarkumar Patel; Amit Shard
Journal:  RSC Med Chem       Date:  2021-05-17

10.  A Novel Computational Method for the Identification of Potential miRNA-Disease Association Based on Symmetric Non-negative Matrix Factorization and Kronecker Regularized Least Square.

Authors:  Yan Zhao; Xing Chen; Jun Yin
Journal:  Front Genet       Date:  2018-08-21       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.